We are live on
!
Find out more
PCH
Polar Capital Holdings Portfolio holdings
AUM
$42.4B
1-Year Est. Return
181.11%
This Fund
S&P 500
This Quarter
Est. Return
-16.7%
1 Year Est. Return
+181.11%
3 Year Est. Return
+584.8%
5 Year Est. Return
+777.19%
10 Year Est. Return
–
AUM
$17B
AUM Growth
-$5.13B
(-23%)
Cap. Flow
-$794M
Cap. Flow
% of AUM
-4.67%
Top 10 Holdings %
Top 10 Hldgs %
43.02%
Holding
494
New
36
Increased
156
Reduced
156
Closed
61
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Salesforce
CRM
|
+$108M |
| 2 |
Visa
V
|
+$102M |
| 3 |
Mercado Libre
MELI
|
+$73M |
| 4 |
Enphase Energy
ENPH
|
+$58.6M |
| 5 |
Snowflake
SNOW
|
+$57.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$147M |
| 2 |
Y
Alleghany Corp
Y
|
+$137M |
| 3 |
Applied Materials
AMAT
|
+$116M |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$115M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$111M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.66% |
| 2 | Industrials | 25.1% |
| 3 | Healthcare | 17.44% |
| 4 | Financials | 14.96% |
| 5 | Communication Services | 5.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Mirum Pharmaceuticals
MIRM
$6.23B
| $23.6M | 0.14% |
1,212,432
+238,723
| +25% | +$5.63M |
|
127
SS&C Technologies
SSNC
$18.8B
| $23.1M | 0.14% |
397,760
| – | – |
|
128
Supernus Pharmaceuticals
SUPN
$2.4B
| $23M | 0.13% |
794,120
-83,825
| -10% | -$2.4M |
|
129
James River Group Holdings
JRVR
$182M
| $22.9M | 0.13% |
925,000
+25,000
| +3% | +$612K |
|
130
Paycom
PAYC
$10B
| $22.7M | 0.13% |
80,985
+46,404
| +134% | +$13.7M |
|
131
Adicet Bio
ACET
$88.7M
| $22.5M | 0.13% |
96,479
| – | – |
|
132
Intercontinental Exchange
ICE
$87.9B
| $22.5M | 0.13% |
238,830
+12,127
| +5% | +$1.3M |
|
133
Cenovus Energy
CVE
$62B
| $22.3M | 0.13% |
1,021,087
-228,945
| -18% | -$4.56M |
|
134
LPL Financial
LPLA
$27.2B
| $22.2M | 0.13% |
120,262
-9,596
| -7% | -$1.82M |
|
135
AtriCure
ATRC
$2.8B
| $21.6M | 0.13% |
528,858
| – | – |
|
136
Tenet Healthcare
THC
$20.8B
| $21.6M | 0.13% |
410,570
+245,570
| +149% | +$17.1M |
|
137
Canadian Natural Resources
CNQ
$105B
| $21.5M | 0.13% |
713,070
-256,872
| -26% | -$7.81M |
|
138
Ametek
AME
$53.4B
| $21.4M | 0.13% |
194,481
+48,231
| +33% | +$5.86M |
|
139
Centene
CNC
$33.7B
| $21.1M | 0.12% |
249,371
-2,744
| -1% | -$228K |
|
140
Atlassian
TEAM
$48.2B
| $20.7M | 0.12% |
110,382
+42,590
| +63% | +$9.09M |
|
141
Sea Limited
SE
$64.9B
| $20.5M | 0.12% |
307,066
+21,829
| +8% | +$1.86M |
|
142
Booking.com
BKNG
$130B
| $20.2M | 0.12% |
289,100
+64,025
| +28% | +$5.46M |
|
|
DCPH
143
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $19.7M | 0.12% |
+1,500,000
| New | +$16.6M |
|
144
Intuitive Surgical
ISRG
$132B
| $19.3M | 0.11% |
96,239
+39,627
| +70% | +$9.3M |
|
145
BioMarin Pharmaceuticals
BMRN
$12.7B
| $18.6M | 0.11% |
225,000
-275,000
| -55% | -$21.9M |
|
146
Freshworks
FRSH
$3.29B
| $18.1M | 0.11% |
+1,374,713
| New | +$21.4M |
|
|
ISEE
147
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $18M | 0.11% |
1,868,628
| – | – |
|
148
Affiliated Managers Group
AMG
$8.94B
| $17.9M | 0.11% |
153,819
-4,285
| -3% | -$551K |
|
149
Celldex Therapeutics
CLDX
$3.02B
| $17.5M | 0.1% |
647,420
-602,580
| -48% | -$17.5M |
|
|
DAWN
150
DELISTED
Day One Biopharmaceuticals
DAWN
| $17.4M | 0.1% |
+971,696
| New | +$10M |
|
Similar funds
GAM
SAM
Polar Capital Holdings's Q2 2022 Portfolio in Review
As of Q2 2022, Polar Capital Holdings held 494 positions worth $17B, down 23% from $22.2B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Polar Capital Holdings withdrew a net $794M in Q2 2022, closing 61 positions and reducing 156 holdings. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $147M position sold in full.
By sector, the portfolio is most concentrated in Technology at 31% of assets, down from 33% a quarter earlier, followed by Industrials and Healthcare.
Against the trend, Polar Capital Holdings opened a new position in Sanofi worth $36.3M.
- Polar Capital Holdings's largest Q2 2022 buy was Sanofi: 725,000 shares worth $36.3M.
- Polar Capital Holdings added most to Salesforce in Q2 2022, an estimated $108M increase.
- Polar Capital Holdings's biggest Q2 2022 reduction was Applied Materials, cutting an estimated $116M.
- Polar Capital Holdings fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q2 2022, selling an estimated $147M.
- Polar Capital Holdings's ten largest holdings make up 43% of its $17B portfolio in Q2 2022.
- Polar Capital Holdings opened 36 new positions and closed 61 in Q2 2022.
- Polar Capital Holdings's portfolio value fell 23% quarter-over-quarter to $17B.
Based on Polar Capital Holdings's 13F filing for Q2 2022, filed 15 Aug 2022.